1. Home
  2. IPHA vs RPT Comparison

IPHA vs RPT Comparison

Compare IPHA & RPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • RPT
  • Stock Information
  • Founded
  • IPHA 1999
  • RPT 2014
  • Country
  • IPHA France
  • RPT United States
  • Employees
  • IPHA N/A
  • RPT N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • RPT
  • Sector
  • IPHA Health Care
  • RPT
  • Exchange
  • IPHA Nasdaq
  • RPT NYSE
  • Market Cap
  • IPHA 150.9M
  • RPT 139.4M
  • IPO Year
  • IPHA 2019
  • RPT N/A
  • Fundamental
  • Price
  • IPHA $1.95
  • RPT $3.23
  • Analyst Decision
  • IPHA Strong Buy
  • RPT Strong Buy
  • Analyst Count
  • IPHA 1
  • RPT 1
  • Target Price
  • IPHA $11.50
  • RPT $4.00
  • AVG Volume (30 Days)
  • IPHA 50.9K
  • RPT 162.2K
  • Earning Date
  • IPHA 03-20-2025
  • RPT 01-01-0001
  • Dividend Yield
  • IPHA N/A
  • RPT 7.59%
  • EPS Growth
  • IPHA N/A
  • RPT N/A
  • EPS
  • IPHA N/A
  • RPT N/A
  • Revenue
  • IPHA $36,202,722.00
  • RPT N/A
  • Revenue This Year
  • IPHA N/A
  • RPT N/A
  • Revenue Next Year
  • IPHA $101.65
  • RPT N/A
  • P/E Ratio
  • IPHA N/A
  • RPT N/A
  • Revenue Growth
  • IPHA N/A
  • RPT N/A
  • 52 Week Low
  • IPHA $1.29
  • RPT $2.65
  • 52 Week High
  • IPHA $3.51
  • RPT $5.76
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 56.50
  • RPT N/A
  • Support Level
  • IPHA $1.72
  • RPT N/A
  • Resistance Level
  • IPHA $1.92
  • RPT N/A
  • Average True Range (ATR)
  • IPHA 0.11
  • RPT 0.00
  • MACD
  • IPHA 0.02
  • RPT 0.00
  • Stochastic Oscillator
  • IPHA 89.74
  • RPT 0.00

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About RPT RITHM PROPERTY TRUST INC

Rithm Property Trust Inc is a real estate investment trust (REIT) externally managed by an affiliate of Rithm Capital Corp. (Rithm). The group is embarking on a new commercial real estate-focused investment. Its tailored approach to investment management seeks to generate attractive risk-adjusted returns for stockholders over the long term through dividends and capital appreciation.

Share on Social Networks: